Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors. - Wikidata - awgldk - TriplyDB

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

http://www.wikidata.org/entity/Q35201826

about

Evolution of animal models in cancer vaccine development In situ immunization via non-surgical ablation to prevent local and distant tumor recurrence.Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers.On the potential of oncolytic virotherapy for the treatment of canine cancers.

P2860

Q28080739-EBAC5C2C-2AD5-427C-A8EE-49AA6DC5C4CB Q34475389-FA0010A4-FF6C-44E5-AEBE-0245154EA7BF Q35815995-4B8B3594-7365-4776-97CF-E114B0EE4FC4 Q36594178-AC73430B-84D6-4493-959D-8662C7D7F89A Q37031925-1CF5DC1D-C8CA-44EA-A0A9-A032C28CF09F

P2860

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

http://www.wikidata.org/entity/Q35201826

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

@ast

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

@en

type

label

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

@ast

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

@en

prefLabel

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

@ast

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

@en

P1433

Q35201826-5EAAC0AE-F766-416E-9C6C-41DBDC81564E

P1476

Q35201826-175C5CF2-C683-4752-8E3F-89C1250A9E23

P2093

Q35201826-23F0C0D2-D0F5-43D5-A912-2C94CDD53394

Q35201826-34BA74A8-CEC7-4D13-833A-1B0384027212

Q35201826-38E3074C-8265-4F22-923E-F716FDC88ABB

Q35201826-DD7BF299-BB79-4502-ADBC-9DAF93326ED5

Q35201826-E0C59778-AE2E-49BC-99E1-223B7C853989

Q35201826-E86A525B-A782-4CAB-8EF8-2BA38EE51B3D

P2860

Q35201826-01314F4F-D941-44C2-9337-01AB149897E2

Q35201826-06DE2400-2D76-4057-856D-5DF971D06D1F

Q35201826-08D329FE-8B4D-4ED6-8764-C1D40E101E33

Q35201826-0CC76164-7444-4DA3-98C7-AA7AD4ADBEB9

Q35201826-14C2B613-AF42-4A69-8CBA-42519CB78D16

Q35201826-14EEA461-D470-427F-8B00-4841E84D0075

Q35201826-1AC4D5D6-55CA-4450-AABC-F778940F7AC2

Q35201826-2041B41B-CCDA-4138-88F3-E63F8A8D5A06

Q35201826-2CA10D80-86E2-4BD9-8828-BF7E9DFEA923

Q35201826-34C6B5E5-3E9F-414E-97B8-22BBD70E7C16

P304

Q35201826-ACDC013D-A8D1-4AFE-BA43-B363D43928EA

P31

Q35201826-86A28EFD-B8F7-4A03-AA41-9303A5AC2B7E

P356

Q35201826-F63DC92D-4F47-49DE-9802-810B0F8B3733

P433

Q35201826-FFC8A613-5F13-4164-BA9D-DC312A5FE932

P478

Q35201826-DF62435B-5EE9-4519-8170-D13D10935C36

P50

Q35201826-52AE021E-08E1-44F9-A714-AD0F5325C86A

Q35201826-727E98C2-6335-4FE6-97B5-1510F7F5FA2D

P577

Q35201826-176EE571-0256-47FD-9B7A-6793D505FB51

P5875

Q35201826-0D16F9B4-142F-45F8-AE1A-E856DED8A064

P698

Q35201826-1199DBBC-275B-4664-A67E-EA761832A2D7

P921

Q35201826-85944ACD-4F81-4E82-BBA0-14ECA11BADEE

Q35201826-9E495135-B4E5-455A-B482-3882E4B85E6D

Q35201826-F4297341-ACE9-4169-BEAD-1627AB23F68E

P932

Q35201826-E1316E66-ABA6-4EC0-AB7F-881C67FD370E

P356

2162402X.2014.984523

P1433

P1476

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors.

@en

P2093

Ilham Bettahi

http://www.w3.org/2001/XMLSchema#string

Jesse Veenstra

http://www.w3.org/2001/XMLSchema#string

Kenneth Barton

http://www.w3.org/2001/XMLSchema#string

Stephanie Munns

http://www.w3.org/2001/XMLSchema#string

Svend Freytag

http://www.w3.org/2001/XMLSchema#string

Wei-Zen Wei

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer

Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.

Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species

Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate

Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer

DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.

Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression.

Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice.

Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.

Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.

P304

e984523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/2162402X.2014.984523

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Heather M Gibson

Jayne Bissonette

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272395061

http://www.w3.org/2001/XMLSchema#string

P698

25949865

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

4368120

http://www.w3.org/2001/XMLSchema#string